经颈静脉肝内门体分流术治疗肝硬化顽固性腹水的现状

王澜静; 姚欣; 秦建平; 汤善宏

doi:10.3969/j.issn.1001-5256.2022.11.034

经颈静脉肝内门体分流术治疗肝硬化顽固性腹水的现状

DOI: 10.3969/j.issn.1001-5256.2022.11.034

王澜静^{1, 2},
姚欣¹,
秦建平¹,
汤善宏^{1, 2, , ,}

1.
西部战区总医院消化内科，成都 610083
2.
西南医科大学附属医院消化内科，四川泸州 646099

基金项目:

四川省卫生健康委员会科研课题 (20PJ180)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王澜静参与拟定写作思路，收集分析文献，撰写论文及修改；姚欣参与指导撰写文章及论文修改；秦建平负责拟定写作思路，指导撰写文章及论文修改；汤善宏负责指导撰写文章，论文修改及最后定稿。

详细信息

通信作者:
汤善宏，15928956390@163.com

计量
- 文章访问数: 338
- HTML全文浏览量: 80
- PDF下载量: 50
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-22
- 录用日期: 2022-05-07
- 出版日期: 2022-11-20

TIPS for treatment of refractory ascites in cirrhosis

Lanjing WANG^{1, 2},
Xin YAO¹,
Jianping QIN¹,
Shanhong TANG^{1, 2
, ,
,}

1.
Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
2.
Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, China

Research funding:

Scientific Research Project of Sichuan Provincial Health Commission (20PJ180)

More Information

Corresponding author: TANG Shanhong, 15928956390@163.com(ORCID: 0000-0001-6652-2942)

摘要

摘要: 顽固性腹水是肝硬化失代偿期门静脉高压的并发症之一，其治疗难度大，病死率高。目前经颈静脉肝内门体分流术(TIPS)作为顽固性腹水的二线治疗，能通过降低门静脉压力来改善腹水症状。国内外大量研究已经提出，使用覆膜TIPS支架，谨慎选择适用人群可以改善顽固性腹水患者的预后，因此有学者提出TIPS可作为顽固性腹水的一线治疗手段。本文将全面介绍国内外TIPS治疗肝硬化顽固性腹水的现状，并对相关研究进展进行阐述，旨在推动我国TIPS治疗顽固性腹水相关研究的发展。
- 肝硬化 /
- 腹水 /
- 门体分流术，经颈静脉肝内 /
- 高血压, 门静脉
Abstract: Refractory ascites (RA) is one of the complications of portal hypertension in decompensated cirrhosis. It is hard to treat RA and there is high mortality in patients with RA. Nowadays, Transjugular Intrahepatic Portosystemic Shunt (TIPS) is used as a second-line treatment for RA. TIPS can improve the clinical symptoms of ascites by reducing the pressure of portal vein. Accumulated studies have proposed that applications of polytetrafluoroethylene covered stents and careful selection of applied patients can improve the prognosis of RA patients. Therefore, some scholars propose that TIPS can be used as one of the first-line treatments for RA. This review will comprehensively summarize current understanding of TIPS in treating RA patients and elaborate the most recently updated progress of the relevant researches, aiming to promote the development of studies on using TIPS as a treatment for RA patients in China.
- Liver Cirrhosis /
- Ascites /
- Portasystemic Shunt, Transjugular Intrahepatic /
- Hypertension, Portal

HTML全文

参考文献(37)

[1]	NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305. DOI: 10.1080/17474124.2018.1555469.
[2]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70(1): 9-29. DOI: 10.1136/gutjnl-2020-321790.
[3]	LARRUE H, VINEL JP, BUREAU C. Management of severe and refractory ascites[J]. Clin Liver Dis, 2021, 25(2): 431-440. DOI: 10.1016/j.cld.2021.01.010.
[4]	MØLLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38(4): 570-580. DOI: 10.1111/liv.13589.
[5]	ADEBAYO D, NEONG SF, WONG F. Refractory ascites in liver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1): 40-47. DOI: 10.1038/s41395-018-0185-6.
[6]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[7]	D'AMICO G, MORABITO A, D'AMICO M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576. DOI: 10.1016/j.jhep.2017.10.020.
[8]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[9]	GARCÍA-PAGÁN JC, SAFFO S, MANDORFER M, et al. Where does TIPS fit in the management of patients with cirrhosis?[J]. JHEP Rep, 2020, 2(4): 100122. DOI: 10.1016/j.jhepr.2020.100122.
[10]	Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[11]	QIN JP, TANG W, TANG SH, et al. Modified transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension of liver cirrhosis[J]. Chin J Dig, 2014, 34(1): 33-36. DOI: 10.3760/cma.j.issn.0254-1432.2014.01.012. 秦建平, 唐文, 汤善宏, 等. 改良经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症[J]. 中华消化杂志, 2014, 34(1): 33-36. DOI: 10.3760/cma.j.issn.0254-1432.2014.01.012.
[12]	TANG SH, QIN JP, SHU QF, et al. The imaging guidance for the portal vein branch puncturing in performing TIPS: recent progress in research[J]. J Intervent Radiol, 2014, 23(7): 640-643. DOI: 10.3969/j.issn.1008-794X.2014.07.022. 汤善宏, 秦建平, 束庆飞, 等. TIPS术中引导门静脉分支穿刺方法[J]. 介入放射学杂志, 2014, 23(7): 640-643. DOI: 10.3969/j.issn.1008-794X.2014.07.022.
[13]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[14]	ARROYO V, GINÈS P, GERBES AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club[J]. Hepatology, 1996, 23(1): 164-176. DOI: 10.1002/hep.510230122.
[15]	SUN MY, TANG SH, ZENG WZ. An excerpt of 2017 KASL clinical practice guidelines for fiver cirrhosis: Ascites and related complications[J]. J Clin Hepatol, 2018, 34(9): 1877-1878. DOI: 10.3969/j.issn.1001-5256.2018.09.010. 孙梦滢, 汤善宏, 曾维政. 《2017年韩国肝病学会临床实践指南: 肝硬化-腹水及相关并发症》摘译[J]. 临床肝胆病杂志, 2018, 34(9): 1877-1878. DOI: 10.3969/j.issn.1001-5256.2018.09.010.
[16]	FUKUI H, SAITO H, UENO Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol, 2016, 51(7): 629-650. DOI: 10.1007/s00535-016-1216-y.
[17]	ZHANG X, WANG SZ, ZHENG JF, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients[J]. World J Gastroenterol, 2014, 20(32): 11400-11405. DOI: 10.3748/wjg.v20.i32.11400.
[18]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662. DOI: 10.1016/j.cgh.2021.07.018.
[19]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[20]	BOSCH J. Small diameter shunts should lead to safe expansion of the use of TIPS[J]. J Hepatol, 2021, 74(1): 230-234. DOI: 10.1016/j.jhep.2020.09.018.
[21]	BUREAU C, THABUT D, OBERTI F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. DOI: 10.1053/j.gastro.2016.09.016.
[22]	TAN HK, JAMES PD, SNIDERMAN KW, et al. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion[J]. J Gastroenterol Hepatol, 2015, 30(2): 389-395. DOI: 10.1111/jgh.12725.
[23]	PARVINIAN A, BUI JT, KNUTTINEN MG, et al. Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites[J]. Diagn Interv Radiol, 2014, 20(1): 58-64. DOI: 10.5152/dir.2013.13131.
[24]	SALERNO F, CAMMÀ C, ENEA M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data[J]. Gastroenterology, 2007, 133(3): 825-834. DOI: 10.1053/j.gastro.2007.06.020.
[25]	SRINIVASA RN, SRINIVASA RN, CHICK J, et al. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: Hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter[J]. Cardiovasc Intervent Radiol, 2018, 41(3): 518-521. DOI: 10.1007/s00270-017-1807-x.
[26]	MIRAGLIA R, MARUZZELLI L, DI PIAZZA A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: Prospective, single-center, preliminary experience[J]. Cardiovasc Intervent Radiol, 2019, 42(1): 78-86. DOI: 10.1007/s00270-018-2040-y.
[27]	TREBICKA J, BASTGEN D, BYRTUS J, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2793-2799. e1. DOI: 10.1016/j.cgh.2019.03.042.
[28]	PIEPER CC, JANSEN C, MEYER C, et al. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts-A three-dimensional sonography study[J]. J Vasc Interv Radiol, 2017, 28(1): 117-125. DOI: 10.1016/j.jvir.2016.06.023.
[29]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[30]	SCHEPIS F, VIZZUTTI F, GARCIA-TSAO G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1153-1162. e7. DOI: 10.1016/j.cgh.2018.01.029.
[31]	BAI M, QI XS, YANG ZP, et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis[J]. World J Gastroenterol, 2014, 20(10): 2704-2714. DOI: 10.3748/wjg.v20.i10.2704.
[32]	BUCSICS T, HOFFMAN S, GRVNBERGER J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis[J]. Liver Int, 2018, 38(6): 1036-1044. DOI: 10.1111/liv.13615.
[33]	SHEN NT, SCHNEIDER Y, CONGLY SE, et al. Cost effectiveness of early insertion of transjugular intrahepatic portosystemic shunts for recurrent ascites[J]. Clin Gastroenterol Hepatol, 2018, 16(9): 1503-1510. e3. DOI: 10.1016/j.cgh.2018.03.027.
[34]	POSE E, CARDENAS A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention[J]. Dig Dis, 2017, 35(4): 402-410. DOI: 10.1159/000456595.
[35]	ALLEGRETTI AS, ORTIZ G, CUI J, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: A matched cohort analysis[J]. Am J Kidney Dis, 2016, 68(3): 381-391. DOI: 10.1053/j.ajkd.2016.02.041.
[36]	YAO X, ZHOU H, HUANG S, et al. Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis[J]. World J Clin Cases, 2021, 9(7): 1532-1542. DOI: 10.12998/wjcc.v9.i7.1532.
[37]	QIN JP, TANG SH, JIANG MD, et al. Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning[J]. World J Gastroenterol, 2015, 21(32): 9623-9629. DOI: 10.3748/wjg.v21.i32.9623.